Artesunate-amodiaquine fixed-dose combination — Competitive Intelligence Brief

Artesunate-amodiaquine fixed-dose combination (Artesunate-amodiaquine fixed-dose combination) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

marketed Antimalarial combination Plasmodium falciparum (multiple parasite targets) Infectious Disease Small molecule

Target snapshot

Artesunate-amodiaquine fixed-dose combination (Artesunate-amodiaquine fixed-dose combination) — Epicentre. Artesunate and amodiaquine work synergistically to kill malaria parasites by generating reactive oxygen species and disrupting parasite metabolism.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Artesunate-amodiaquine fixed-dose combination TARGET	Artesunate-amodiaquine fixed-dose combination	Epicentre	marketed	Antimalarial combination	Plasmodium falciparum (multiple parasite targets)
chlorproguanil-dapsone plus artesunate	chlorproguanil-dapsone plus artesunate	Centers for Disease Control and Prevention	marketed	Antimalarial combination	Dihydrofolate reductase (chlorproguanil/dapsone); mitochondrial function (artesunate)
Artesunate plus Amodiaquine	Artesunate plus Amodiaquine	Bernhard Nocht Institute for Tropical Medicine	marketed	Antimalarial combination therapy	Plasmodium falciparum (multiple parasite targets including heme detoxification pathway and DNA synthesis)
Chloroquine + Primaquine	Chloroquine + Primaquine	U.S. Army Medical Research and Development Command	marketed	Antimalarial combination	Plasmodium parasite heme metabolism and mitochondrial function
artemisinin/naphthoquine	artemisinin/naphthoquine	Ifakara Health Institute	marketed	Antimalarial combination	Plasmodium falciparum heme metabolism and mitochondrial electron transport
Artemether + Lumefantrine	Artemether + Lumefantrine	GlaxoSmithKline	marketed	Antimalarial combination	Plasmodium falciparum hemoglobin metabolism and heme detoxification pathway
Coadministered Artesunate plus Amodiaquine	Coadministered Artesunate plus Amodiaquine	Professor Anders Björkman	marketed	Antimalarial combination therapy	Plasmodium falciparum heme metabolism and protein synthesis

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class